
浏览全部资源
扫码关注微信
中国中医科学院研究生院,北京,100700
纸质出版日期:2022
移动端阅览
张雪雪. 131I联合碳酸锂与131I单用治疗甲状腺功能亢进症的系统评价[J]. 重庆医科大学学报, 2022,47(6):657-661.
Zhang Xuexue. Systematic review of131I combined with lithium carbonate and 131I alone in the treatment of hyperthyroidism[J]. Journal of chongqing medical university, 2022, 47(6): 657-661.
目的: 评价131I联合碳酸锂治疗甲状腺功能亢进症(甲亢)是否优于131I单用。方法: 检索PubMed、Web of Science、the Cochrane Library、CNKI、CBM、万方数据库中2020年4月之前发表的文献。查找131I联合碳酸锂与131I单用治疗甲亢的随机对照试验(randomized controlled trial,RCT)。采用Cochrane系统评价手册推荐的风险偏倚评价工具对纳入文献的质量进行评价,运用Review Manager 5.3对提取的数据进行Meta分析,不能合并者采取描述性分析。结果: 本研究共纳入14个RCT,共纳入1 567名患者,其中试验组808人,对照组759人。数据合并结果表明,131I联合碳酸锂与131I单用治疗甲亢相比,在随访第3个月(RR=1.24,95% CI=1.09~1.41,P=0.001)和第12个月(RR=1.18,95% CI=1.04~1.34,P=0.010),甲亢治愈率差异有统计学意义。在随访第3个月,甲亢复发率差异有统计学意义(RR=0.39,95% CI=0.18~0.85,P=0.02)。在随访第1个月,甲减发生率差异有统计学意义(RR=1.39,95% CI=1.06~1.84,P=0.02)。在随访第3个月(RR=1.02,95% CI=0.97~1.08,P=0.48)和第6个月(RR=1.06,95% CI=0.86~1.30,P=0.60),甲亢治疗总有效率差异无统计学意义。在治疗第1个月,甲状腺大小差异无统计学意义(SMD=-0.26,95% CI=-0.61~0.09,P=0.15)。结论: 系统评价结果显示,131I联合碳酸锂治疗甲亢,随访第3、第12个月的甲亢治愈率,随访第3个月的甲亢复发率,随访第12个月的甲减发生率优于131I单用,而甲亢治疗总有效率、甲状腺大小与131I单用均无统计学差异。但由于纳入文献的质量偏低,其结论仍需要更多大样本、多中心、试验设计规范的RCT验证。
Objective: To evaluate whether131I combined with lithium carbonate is better than131I alone in the treatment of hyperthyroidism. Methods: The literature published before April 2020 in PubMed
Web of Science
the Cochrane Library
CNKI
CBM and Wanfang databases was retrieved. Randomized controlled trials (RCTs) of131I combined with lithium carbonate and131I alone in the treatment of hyperthyroidism were searched. The risk bias evaluation tool recommended by Cochrane system evaluation manual was used to evaluate the quality of the included literature
and Review Manager 5.3 was used to perform Meta-analysis on the extracted data
while descriptive analysis was used for those that could not be combined. Results: This study included 14 RCTs for analysis
including 1 567 patients
808 in the experimental group and 759 in the control group. The results showed that there was significant difference in the cure rate of hyperthyroidism between131I combined with lithium carbonate and131I alone at the third month (RR=1.24
95% CI=1.09-1.41
P=0.001) and 12th month (RR=1.18
95% CI=1.04-1.34
P=0.010). There was significant difference in the recurrence rate of hyperthyroidism at the third month (RR=0.39
95% CI=0.18-0.85
P=0.02)
and the incidence of hypothyroidism in one month (RR=1.39
95% CI=1.06-1.84
P=0.02)
and no significant difference in the total effective rate of hyperthyroidism treatment at the third month (RR=1.02
95% CI=0.97-1.08
P=0.48) and sixth month (RR=1.06
95% CI=0.86-1.30
P=0.60). There was no significant difference in thyroid size at 1 month (SMD=-0.26
95% CI=-0.61-0.09
P=0.15). Conclusion: The results of systematic review show that131I combined with lithium carbonate in the treatment of hyperthyroidism
the cure rate
recurrence rate of hyperthyroidism in the third and 12th month and the incidence of hypothyroidism in the 12th month are better than those of131I alone
but there is no significant difference in the total effectiverateandthyroidsizeof hyperthyroidism treatment. However
due to the low quality of the included literature
its results and conclusions still need to be verified by more RCTs with large samples
multi centers
and test design specifications.
0
浏览量
3
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621